Promoting Inclusion of Members of Racial and Ethnic Minority Groups in Cancer Drug Development

被引：22

作者：

Fashoyin-Aje, Lola ^{[1
]}

Beaver, Julia A. ^{[1
]}

Pazdur, Richard ^{[1
]}

机构：

[1] US FDA, Oncol Ctr Excellence, 10903 New Hampshire Ave,Bldg 22, Silver Spring, MD 20993 USA

来源：

JAMA ONCOLOGY | 2021年 / 7卷 / 10期

关键词：

D O I：

10.1001/jamaoncol.2021.2137

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1445 / 1446

页数：2

共 5 条

[1]

[Anonymous], 2016, Collection of race and ethnicity data in clinical trials: Guidance for industry and food and drug administration staff

[2] The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer [J].

Armour, A. A. ;

Watkins, C. L. .

EUROPEAN RESPIRATORY REVIEW, 2010, 19 (117) :186-196

[3] Racial composition in trials supporting the US approval of anti-cancer new molecular entities (NMEs): 2011-2016. [J].

Fashoyin-Aje, Lola A. ;

Fernandes, Laura L. ;

Lemery, Steven ;

Keegan, Patricia ;

Sridhara, Rajeshwari ;

Bull, Jonca C. ;

Pazdur, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[4]

U.S. Food Drug Administration, 2020, Enhancing the diversity of clinical trial populations: eligibility criteria, enrollment practices, and trial designs guidance for industry Internet

[5] Under-Representation of Racial Minorities in Prostate Cancer Studies Submitted to the US Food and Drug Administration to Support Potential Marketing Approval, 1993-2013 [J].

Wissing, Michel D. ;

Kluetz, Paul G. ;

Ning, Yang-Min ;

Bull, Jonca ;

Merenda, Christine ;

Murgo, Anthony J. ;

Pazdur, Richard .

CANCER, 2014, 120 (19) :3025-3032

← 1 →